drugset / Trial / NCT07115095
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, randomized study to compare the efficacy of TP (Taxane plus Carboplatin) chemotherapy combined with dual-HER2 blockade (trastuzumab and pertuzumab) versus TP chemotherapy plus single-HER2 blockade (trastuzumab) in patients with HER2-positive breast cancer. The study aims to evaluate treatment response and the clinical value of serum tumor markers (CEA, CA125, and CA153) in assessing therapeutic efficacy.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Background | Carboplatin | Small molecule | 400 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 150 mg/m2 | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 8 mg/kg | Intravenous |